Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ESMO 2017 in-depth: TONIC trial

This year the ESMO congress took place in Madrid from 8 - 12 September.

Marleen Kok, MD, PhD at The Netherlands Cancer Institute in Amsterdam, explains the design and first results of the TONIC trial. This adaptive phase II trial evaluated the response rate to nivolumab after induction treatment in patients with triple-negative breast cancer.

  • This program is editorially independent and is financially made possible by

Related items

Congress news

ESMO 2017 in-depth: Neoadjuvant chemotherapy in cervical cancer

This year the ESMO congress took place in Madrid from 8 - 12 September. Sudeep Gupta, Professor of Medical Oncology at Tata Memorial Hospital in Mumbai, explains the design and results of his trial, that examined whether neoadjuvant chemotherapy followed by surgical removal of the tumour could improve outcomes in patients with locally advanced cervical cancer compared to standard treatment with chemoradiation.

Congress news

ESMO 2017 in-depth: KEYNOTE-040 trial

This year the ESMO congress took place in Madrid from 8 - 12 September. E. This phase III trial evaluated the efficacy of checkpoint inhibitor pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy.

Congress news

ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.

Congress news

ESMO 2017 in-depth: IFCT-0302 trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Prof. Virginie Westeel, head of the Thoracic Oncology unit in the University Hospital of Besançon, explains the design and results of the IFCT-0302 trial. This randomised trial compared two follow-up protocols for patients with completely resected non-small cell lung cancer.

Congress news

ASCO GU 2018: Progression after IO combination regimens mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

Congress news

ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

Congress news

WCM 2017 Highlights: Immunotherapy

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma. This highlight consists of the following parts: Prof. Caroline Robert, MD – dermatologist, Institute Gustave-Roussy, Paris, France: The latest results of immunotherapy in melanoma Alain Algazi, MD – oncologist, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA: Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma Sapna Patel, MD – oncologist, MD Anderson Cancer Center, Houston, USA: A phase II study of glembatumumab vedotin for metastatic uveal melanoma